Charles W. Newton Acquires 200,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CFO Charles W. Newton acquired 200,000 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $0.56 per share, for a total transaction of $112,000.00. Following the completion of the purchase, the chief financial officer now directly owns 200,000 shares of the company’s stock, valued at $112,000. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Lyell Immunopharma Trading Down 6.5 %

LYEL traded down $0.03 on Tuesday, hitting $0.48. 1,199,720 shares of the stock traded hands, compared to its average volume of 1,043,773. Lyell Immunopharma, Inc. has a 52 week low of $0.48 and a 52 week high of $3.15. The firm has a market capitalization of $142.80 million, a PE ratio of -0.61 and a beta of -0.41. The business has a fifty day moving average price of $0.62 and a two-hundred day moving average price of $0.90.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.52). Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The firm had revenue of $0.01 million for the quarter. On average, equities research analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently added to or reduced their stakes in LYEL. Centiva Capital LP acquired a new stake in Lyell Immunopharma during the third quarter valued at approximately $31,000. Graham Capital Management L.P. acquired a new stake in Lyell Immunopharma during the fourth quarter valued at approximately $33,000. RPO LLC acquired a new stake in Lyell Immunopharma during the fourth quarter valued at approximately $42,000. Intech Investment Management LLC acquired a new stake in Lyell Immunopharma during the third quarter valued at approximately $52,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Lyell Immunopharma during the third quarter valued at approximately $52,000. 66.05% of the stock is owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.